Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing immunomodulatory therapies for neurodegenerative, autoimmune, and inflammatory diseases. The company operates within the biotechnology and life sciences industries, with a specific emphasis on regulating T cell biology to restore immune balance in chronic disease states. Its core strategy centers on enhancing the function of regulatory T cells (Tregs) to suppress harmful inflammation while preserving protective immune responses.
The company’s primary revenue drivers are its clinical development programs and strategic collaborations, as it does not currently generate product sales. Coya’s lead programs target indications such as amyotrophic lateral sclerosis (ALS), Alzheimer’s disease, and Parkinson’s disease. The company positions itself uniquely by combining low-dose biologics and cytokine-based therapies designed to selectively activate Tregs, differentiating its approach from broader immunosuppressive treatments. Founded in 2014, Coya Therapeutics evolved from early academic and translational research into a publicly traded company, completing its initial public offering in 2022 to support clinical expansion.
Business Operations
Coya Therapeutics’ operations are organized around its clinical development pipeline, which constitutes its primary business activity. Key programs include COYA 101, a combination of low-dose interleukin-2 and CTLA4-Ig for ALS, and COYA 302, an interleukin-2 fusion protein developed in collaboration with Dr. Reddy’s Laboratories Ltd. Revenue generation is currently limited to collaboration-related payments and research funding, with no commercial-stage products on the market.
The company conducts research and development primarily in the United States, leveraging a network of contract research organizations for preclinical studies, manufacturing, and clinical trials. Coya controls proprietary know-how related to Treg biology, dosing strategies, and combination immunotherapies. Its most significant partnership is with Dr. Reddy’s Laboratories Ltd., which supports development, manufacturing, and potential commercialization of select pipeline assets, while Coya retains significant economic and development participation.
Strategic Position & Investments
Coya Therapeutics’ strategic direction is focused on advancing its lead assets through mid-stage clinical trials while expanding its pipeline through internal research and selective partnerships. Growth initiatives emphasize indications with high unmet medical need and clear immunological drivers, particularly neurodegenerative diseases where inflammation is increasingly recognized as a contributing factor. The company prioritizes capital efficiency by advancing combination therapies that utilize known biologics with established safety profiles.
Rather than pursuing large-scale acquisitions, Coya has emphasized strategic collaborations and licensing arrangements. Its partnership with Dr. Reddy’s Laboratories Ltd. represents its most notable strategic investment, providing access to global development and manufacturing capabilities. The company is also involved in emerging areas of immunology focused on precision immune modulation, specifically therapies that selectively enhance regulatory immune pathways rather than broadly suppressing immune activity.
Geographic Footprint
Coya Therapeutics is headquartered in Houston, Texas, and its primary operations are based in the United States. Clinical development activities are conducted predominantly in North America, with trial sites selected based on regulatory pathways and patient availability. The company does not currently maintain large-scale international offices but has an expanding global footprint through its strategic partners.
International influence is primarily achieved through collaborative agreements rather than direct operations. Through its partnership with Dr. Reddy’s Laboratories Ltd., Coya has exposure to development and potential commercialization activities in India, Europe, and other international markets. This model allows the company to participate in global markets while maintaining a lean internal operational structure.
Leadership & Governance
Coya Therapeutics is led by an executive team with experience in biotechnology, immunology, and drug development. The leadership emphasizes a science-driven strategy focused on disciplined clinical execution and strategic partnerships to maximize shareholder value while addressing significant unmet medical needs.
Key executives include:
- Arun Swaminathan – Chief Executive Officer
- Howard Berman, MD, PhD – Executive Chairman
- Fred Grossman, DO, FANA – Chief Medical Officer
- Joseph E. Truax – Chief Financial Officer
The company’s governance framework aligns with U.S. public company standards, with oversight provided by a board comprising executives and independent directors experienced in life sciences, finance, and corporate strategy. Leadership has articulated a vision centered on advancing Treg-based therapies into clinically and commercially viable treatments through rigorous science and strategic collaboration.